Human normal immunoglobulin (Baxter Healthcare)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHuman normal immunoglobulin (Baxter Healthcare)
Drug Alias Name人正常免疫球蛋白-Baxter16% liquid immunoglobulin therapySubcuvia
ClassificationBiologics > Blood componentsBiologics > Protein drugs > Immunoglobulin
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsImmunologic Deficiency SyndromesMotor Neuron DiseasePolyradiculoneuropathy, Chronic Inflammatory Demyelinating
Global Approved IndicationsImmunologic Deficiency Syndromes
Approved Indications in ChinaN/A
Original Approved Country/TerritoryDenmark
Original Approved Date1995/10/01
Country/TerritoryCzechiaSwedenPortugal +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBaxter International Inc
China Registration ClassN/A

Develop Information

Active CompaniesBaxter International Inc
Inactive CompaniesAarhus UniversityBaxter Healthcare Corp
Active IndicationsImmunologic Deficiency Syndromes
Inactive IndicationsMotor Neuron DiseasePolyradiculoneuropathy, Chronic Inflammatory Demyelinating

Other Information

ATC CodeJ06BA
Related LinksN/A